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We report a case of Kaposi sarcoma (KS) and
disseminated infection by Mycobacterium genavense in a
40-year-old HIV-positive man with CD4+ T-cell count
5/mL. He presented with anorexia, diarrhoea, cachexia
and multiple firm violaceous nodules distributed over the
face, neck and upper and lower extremities. Biopsy of a
skin nodule was performed, confirming KS.
Immunoperoxidase staining for human herpesvirus 8 was
strongly positive. Endoscopic examination revealed
erosive duodenopathy. Multiple biopsy samples showed
numerous acid-fast bacilli at direct microscopic
examination. Real-time PCR (RT-PCR) identified M.
genavense. A CT scan showed diffuse pulmonary
infiltrates with a ‘tree-in-bud’ appearance, striking
splenomegaly and abdominal lymphadenopathy. A
bronchoscopy was performed, revealing typical Kaposi’s
lesions in the upper respiratory tract. RT-PCR of
bronchial aspirate identified M. genavense and
Pneumocystis jirovecii. Despite treatment with highly
active antiretroviral therapy, antimycobacterial therapy
and trimethoprim/sulfamethoxazole, the outcome was
fatal.
BACKGROUND
Mycobacterium genavense is a fastidious, non-
tuberculous mycobacterium (NTM), responsible for
disseminated infection among severely immuno-
compromised HIV-positive patients.1 It remains a
diagnostic challenge for physicians and microbiolo-
gists, due to its remarkable clinical similarities to
Mycobacterium avium complex (MAC) infection.
Kaposi sarcoma (KS) is the second most frequent
cancer in HIV-infected patients worldwide and
occurs in more than 50% of cases in late stages of
HIV infection.2 Opportunistic infections have been
associated with the induction and/or exacerbation
of pre-existing KS, but few cases have been
reported.3
CASE PRESENTATION
In September 2014, a 40-year-old HIV-positive
man was admitted to the hospital, with 3 months
of progressive weight loss, diarrhoea and decreased
appetite. He denied fever, night sweats, abdominal
pain, cough, haemoptysis or dyspnoea.
He was known to be HIV positive for 15 years,
and started highly active antiretroviral therapy
(HAART) in August 2009, but was non-adherent to
treatment. In April 2011, he restarted HAART, and
4 months later his CD4+ T-cell count was 188/mL
and HIV viral load was 311 copies/mL. He with-
drew from treatment the following months.
Clinical examination revealed a cachectic, afeb-
rile man, with pale and dry mucous membranes.
Cardiopulmonary auscultation was normal.
Abdominal examination was characterised by mod-
erate ascites and painful splenomegaly. Multiple
firm, non-ulcerated, violaceous nodules scattered
over the face, neck (figure 1), and upper and lower
extremities, were also noted.
Laboratory findings were sodium 127 mEq/L,
albumin 1.7 g/dL, serum iron 10 mg/dL, ferritin
1055 ng/mL, transferrin 111 mg/dL, folic acid
1.6 ng/mL, haemoglobin 5.8 g/dL, platelets
53,000/mL, white cell count 1,400/mL, reticulocyte
count 0.2% and C reactive protein 120 mg/L. The
patient’s CD4+ T-cell count was 5/mL and HIV
viral load was 19 509 copies/mL. Serological evalu-
ation for hepatitis B and C, cytomegalovirus,
parvovirus and Toxoplasmosis was negative. Stool
and blood cultures failed to reveal any organism.
Chest radiography showed peribronchial thickening
and septal lines (figure 2).
Biopsy of a skin nodule over the left hand was
performed. Histopathological examination showed
proliferation of small vessels around which elon-
gated spindle cells were observed, confirming KS.
Immunoperoxidase staining for human herpesvirus
8 (HHV-8) was strongly positive.
Endoscopic examination revealed diffuse inflam-
mation of the mucosa of the duodenum. Multiple
biopsy samples were submitted for histological and
molecular biological analysis. Profound macro-
phage infiltration, without granuloma, and the
presence of numerous acid-fast bacilli were found.
Molecular biological analysis of samples taken
Figure 1 Cutaneous Kaposi lesions.
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directly from the biopsy material, using real-time PCR
(RT-PCR), led to the identification of M. genavense.
A CT of the chest and abdomen showed diffuse pulmonary
infiltrates with a ‘tree-in-bud’ appearance (figure 3), numerous
large lymph nodes in the abdomen, moderate volume ascites,
heterogeneous splenic parenchyma with multiple hypodense
nodules and striking splenomegaly. A bronchoscopy was per-
formed, revealing cherry-red, slightly raised tracheal lesions
(figure 4), typical of KS. Owing to the potential risk of bleeding,
biopsy was avoided. Bronchial aspirate direct smear was positive
for acid-fast bacilli, and M. genavense and Pneumocystis jirovecii
were identified using RT-PCR. Bronchial aspirate
Löwenstein-Jensen and mycobacterial growth indicator tube cul-
tures failed to reveal any organism.
Unlike the diagnosis of KS with pulmonary involvement,
which was confirmed by skin biopsy and bronchoscopy, dissemi-
nated M. genavense infection diagnosis was not so clear. This
organism was isolated from non-sterile sites, such as the respira-
tory and gastrointestinal (GI) tracts, however, a high number of
colonies were present. Moreover, the patient was severely
immunocompromised and presented disseminated disease
(weight loss, pancytopenia, splenomegaly, lymphadenopathy),
supporting the diagnosis of disseminated M. genavense infection,
rather than colonisation. Also, even though the patient did not
present respiratory symptoms, P. jirovecii pneumonia was
assumed, due to its isolation from bronchial aspirate and the
presence of diffuse pulmonary infiltrates.
TREATMENT
The patient was started on antiretroviral treatment with daruna-
vir/ritonavir plus abacavir/lamivudine. The direct molecular
diagnosis of M. genavense and P. jirovecii enabled immediate
treatment of the patient with antimycobacterial therapy (rifabu-
tin, ethambutol and clarithromycin) and co-trimoxazole (tri-
methoprim/sulfamethoxazole).
Four days after beginning treatment, the patient presented a
non-pruritic, annular, erythematous skin eruption involving the
upper and lower extremities, and trunk (figure 5). Mucous
membranes were not involved. We assumed a drug-induced skin
eruption due to co-trimoxazole, since it spontaneously resolved
and did not recur after desensitising the patient using a regimen
of gradual incremental exposure over a 14-day period.
Unfortunately, it was not possible to perform a timely skin
biopsy to confirm the diagnosis.
After optimising HAART, our goal was to initiate systemic
chemotherapy for pulmonary KS. However, this was
Figure 2 Chest radiography showing peribronchial thickening and
septal lines.
Figure 4 Bronchoscopy showing violaceous patches in the trachea.
Figure 3 CT of the chest showing diffuse pulmonary infiltrates with a
‘tree-in-bud’ appearance.
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unbearable, due to the patient’s severe pancytopenia and the
concurrent risk of chemotherapy-induced myelosuppression.
OUTCOME AND FOLLOW-UP
The patient experienced a prolonged hospital stay, as he pre-
sented severe cachexia and pancytopenia, with regular need of
red blood cell transfusion. He completed 21 days of treatment
with co-trimoxazole and was continued on HAART and antimy-
cobacterial therapy. Four months later, his CD4+ T-cell count
was 6/mL and HIV viral load was 434 184 copies/mL. He was
assumed to be non-adherent to treatment and died the following
month.
DISCUSSION
M. genavense is a fastidious NTM that is believed to be acquired
through ingestion of the organism from an environmental
source. It has been isolated from the respiratory and GI tracts of
immunocompetent humans.4 This finding supports the hypoth-
esis that M. genavense may colonise the gut and disseminate
from it with progressive immunodeficiency. M. genavense infec-
tion has been reported almost exclusively in patients with AIDS
and an absolute CD4+ T-cell count <100/mL.4 5 It is respon-
sible for 12.8% of all NTM infections in patients with AIDS
and has been described as a pathogen-causing disease with sign-
ificant morbidity and mortality.6
M. genavense infection typically presents as a disseminated
disease, with massive adenopathy and organomegaly, especially
splenomegaly, without respiratory symptoms or pulmonary
involvement. Clinical presentation is strikingly similar to that of
disseminated MAC infection.7 Charles et al8 conducted a retro-
spective multicentre study in France, which illustrated the
variety of clinical presentations of M. genavense: weight loss
(79%), fever (75%), abdominal pain (71%), splenomegaly
(71%), lymphadenopathy (62,5%), diarrhoea (62,5%) and hep-
atomegaly (62,5%).
Owing to the extreme fastidiousness of M. genavense, routine
cultures fail to isolate this organism. Therefore, in most cases,
molecular methods such as RT-PCR and 16S ribosomal RNA
gene sequencing are necessary. Human isolates can be recovered
from cultures of blood, bone marrow, liver, spleen and other
tissue, but require supplemented media for growth.9 In our
case, early diagnosis of M. genavense infection was possible due
to Mycobacterium seen at direct microscopic examination of
duodenum samples and bronchial aspirate, and confirmation
with RT-PCR. However, blood, stool and bronchial aspirate cul-
tures remained negative, confirming the particular difficulty in
growing this organism using standard mycobacterial culture
methods.
When M. genavense is isolated from a usually sterile site,
such as blood, bone marrow, lymph nodes or synovial fluid,
the diagnosis of true infection is usually clear. However, when
it is isolated from non-sterile sites, such as the respiratory or
GI tract, the diagnosis can be less definitive. A case series from
Spain, conducted between 1998 and 2005, identified 26
HIV-infected patients with NTM isolates from sputum.10 As in
our patient, they used clinical criteria to establish a diagnosis
of colonisation versus infection; some of the factors associated
with disease were CD4+ T-cell count <50/mL, weight loss,
haemoglobin <11 g/dL and duration of symptoms longer than
a month.
Owing to the difficulties of growing M. genavense in culture,
in vitro data on drug susceptibility are scarce. Previous studies,
reviewed in the American Thoracic Society Statement, suggest
that most isolates are susceptible to amikacin, rifamycins, fluoro-
quinolones, streptomycin and macrolides.9 Ethambutol and iso-
niazid have limited activity against M. genavense.7 Optimal
treatment has not been established, but therapeutic regimens of
at least three antimycobacterial drugs, including clarithromycin,
during 12–18 months, appear to be more effective.9 In our case,
despite following these guidelines, the outcome was fatal after
5 months of treatment. However, we believe that the patient’s
non-adherence to treatment and his severe immunosuppression
contributed in a large scale to this result.
Besides the diagnosis of disseminated M. genavense infection,
our patient also presented a skin biopsy and bronchoscopy con-
firming the diagnosis of KS with pulmonary involvement. KS is
one of the AIDS-defining skin diseases and is the second most
common neoplasm seen in HIVinfected patients worldwide. It
has reached epidemic proportions in some parts of the world,
such as Southern Africa.2
KS is an angioproliferative cancer of endothelial origin, and is
characterised by its notable clinical heterogeneity, varying from
minimal to fulminant disease, as well as by its ability to progress
or regress based on host-immune factors.11 Its development is
strongly associated with HIV infection, mainly the CD4+ T-cell
count, which seems to be the most important factor, and
HHV-8 infection.12 HIV infection is believed to create a defi-
cient immunological environment within which other oncogenic
viruses, such as HHV-8, can escape immune control and induce
tumour growth.13
Unlike classical forms of KS, which are generally slowly pro-
gressive and limited to the skin, AIDS-related KS is frequently
more aggressive, involving lymph nodes and visceral organs,
which confers significant morbidity and mortality. Cutaneous
KS is characterised by a few or widespread multifocal violaceous
or dark red colour patches, papules, plaques and/or skin
nodules. The range of colours associated with these lesions is
owed to their vascularity. Typically, the lesions are bilateral, sym-
metrically distributed and involve mainly the lower extremities,
face (especially the nose) and genitalia.14 Although these lesions
present a characteristic appearance, KS diagnosis should be con-
firmed by a biopsy whenever possible. Histological examination
is usually characterised by neoangiogenesis and proliferating
spindle-shaped cells combined with an inflammatory infiltrate of
lymphocytes, plasma cells and macrophages.13 Identification of
HHV-8 is possible using immunohistochemical staining.
Figure 5 Annular erythematous eruption of the trunk (resolution
phase).
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In HIV-infected patients, it is common for KS to spread to
extracutaneous sites, such as the mucosal membranes, lymph
nodes and visceral organs, including the GI tract, lungs, liver
and spleen. The oral cavity is frequently affected (33% of
cases). In 40% of cases, GI involvement is present at initial
diagnosis and can occur without cutaneous disease.3 GI lesions
may cause weight loss, abdominal pain, nausea, vomiting and
bleeding, or may be asymptomatic. Likewise, pulmonary KS is
also common, and in 15% of cases, may occur in the absence
of mucocutaneous disease.15 Patients with pulmonary KS may
present with shortness of breath, cough or haemoptysis. In
those who are asymptomatic, pulmonary KS may be found on
a chest radiograph (nodular, interstitial or alveolar infiltrates,
pleural effusion or isolated pulmonary nodule).16 Biopsy of
these lesions should be avoided, due to the potential risk of
bleeding. Therefore, as demonstrated in our case and sup-
ported by the literature, the finding of cherryred, slightly
raised endobronchial lesions at the time of bronchoscopy is
generally sufficient for a presumptive diagnosis of pulmonary
KS.17
AIDS-related KS is usually staged according to the AIDS
Clinical Trials Group classification system, which characterises
cases as good or poor risk prognosis, considering both the KS
and HIV infection.18 Patients are categorised taking into
account tumour burden, immune status (measured by CD4+
T-cell count) and the presence of systemic illness. Those
patients, such as ours, who present with extensive oral cavity
involvement or visceral disease, CD4+ T-cell count lower than
200/mL, and a history of opportunistic infection, thrush or B
symptoms (fever, night sweats, weight loss, diarrhoea), are con-
sidered to have a poor prognosis. However, those who do not
present any of these factors are considered to have a better
prognosis.
AIDS-related KS treatment decisions depend on the disease
stage, symptoms and concurrent complications of HIV infection.
HAART, either alone or in combination with systemic chemo-
therapy, is recommended for all patients with AIDS-related KS,
as it plays a crucial role in preventing disease progression and
reducing tumour burden. It has multiple effects on KS, which
include the inhibition of HIV replication, the improvement of
the immunoresponse against HHV-8 and possibly some direct
antiangiogenic activity of protease inhibitors.19 Systemic chemo-
therapy is generally indicated for patients not responding to
HAART and/or with widespread, symptomatic, rapidly progres-
sive or life-threatening disease.20 The recommended first-line
chemotherapy for KS treatment is pegylated liposomal doxo-
rubicin or liposomal daunorubicin.21 Other agents that have
been used include paclitaxel, bleomycin, vinblastine, vincristine
and etoposide.22
In our patient, the concurrent presence of extensive cutane-
ous KS lesions with pulmonary involvement, severe immuno-
suppression, disseminated M. genavense infection and
P. jirovecii pneumonia, contributed to a poor prognosis. The
patient was immediately started on HAART, but systemic
chemotherapy was never initiated, due to the patient’s severe
pancytopenia and the concomitant risk of chemotherapy-
induced myelosuppression. Similar to that described with
corticosteroid therapy, opportunistic infections have been asso-
ciated with the induction and/or exacerbation of pre-existing
KS, but few cases have been reported.23 24 In our case, we
believe that the patient’s disseminated M. genavense infection
and P. jirovecii pneumonia probably contributed to these effects
on KS, since a high level of proinflammatory cytokines was
observed in this setting.
Learning points
▸ Mycobacterium genavense infection must be considered as a
differential diagnosis of any HIV patient with an absolute
CD4+ T-cell count <100/mL presenting with fever, diarrhoea,
abdominal pain, weight loss and lymphadenopathy.
▸ Since of its culture growth limitations, early diagnosis relies
mostly on molecular methods, such as real-time PCR and
16S ribosomal RNA gene sequencing, which allow rapid
identification of the Mycobacterium.
▸ Therapeutic regimens should consist of at least three
antimycobacterial drugs, including clarithromycin.
▸ AIDS-related Kaposi sarcoma (KS) is frequently aggressive
and presents with disseminated disease, more often
affecting the oral cavity, the gastrointestinal and respiratory
tracts, which confer significant morbidity and mortality.
▸ Highly active antiretroviral therapy is recommended for
virtually all patients with AIDS-related KS, since it is
essential for prevention of disease progression and tumour
burden reduction.
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